SecBot SecBot

BDRX

Biodexa Pharmaceuticals Plc
Nasdaq· Pharmaceutical Preparations· Inc. X0· CIK 0001643918 Biotech & Drug Discovery
—
Market cap
$1.7M
Nano cap
Median target
🔒 Subscribers only
Short interest
18.4K
≈0.4% of shares · −93.2%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2025 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 4 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 6/7
Strongest BULLISH Biodexa announced enrollment of the 100th patient in its registrational Phase 3 trial (Serenta) of eRapa for…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2025: 0 added (0 new), 2 trimmed or exited.

  • Short sellersCOVERING

    Short interest −93.2% to 18.4K shares. 1.0 days to cover, ≈0.4% of shares.

Who's buying

13F· Q2 2025
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT1,989$1.7K
RHUMBLINE ADVISERSNEAR_EXIT69$59.00
UBS Group AGDOUBLED18,832$24.9K
RHUMBLINE ADVISERSDOUBLED315$414.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Feb 2024

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Feb 8, 2024Ladenburg Thalmann
INITIATE
INITIATEBuy

Earnings setup

Estimates
$0.00
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.00$0.00–$0.00—$0.00
Next Q$0.00$0.00–$0.00—$0.00
Current FY$0.00$0.00–$0.00—$0.00
Next FY$0.00$0.00–$0.00—$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 23, 2026
Trading halt
Trading Halt: BDRX — T1 (News Pending)
Biodexa Pharmactls plc ADS | Market: NASDAQ | Code: T1 — News Pending
Oct 22, 2026
Clinical Trial
Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance
Phase 2 · COMPLETED
Oct 13, 2026
Press release
Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP
October 13, 2026 Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP Update on…

Short side

FINRA· Sep 30, 2026
18,380
shares short
-93.2%
vs prior settlement
1.0
days to cover
≈0.4%
of shares outstanding
Trading halts
Oct 23, 2026Resumption ScheduledResumed
Sep 11, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
🔒 Fresh data, subscribers only
Oct 14, 2026 SEC
Biodexa announced enrollment of the 100th patient in its registrational Phase 3 trial (Serenta) of eRapa for Familial…
6-K — Impact 6/10
Oct 8, 2026 SEC
Biodexa Pharmaceuticals announced a mandatory ratio change for its American Depositary Shares (ADSs), effective as a…
6-K — Impact 2/10
Oct 1, 2026 SEC
The SEC declared effective Biodexa Pharmaceuticals' F-1 registration statement (File No. 333-299106) on September 30…
EFFECT — Impact 6/10
Mar 23, 2026 Press
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its…
Impact 4/10
Jun 30, 2025 Inst.
UBS Group AG — NEAR_EXIT
1,989 shares ($1.7K)
Jun 30, 2025 Inst.
RHUMBLINE ADVISERS — NEAR_EXIT
69 shares ($59.00)

SecBot reports

12 filings · 1 press release · 1 bullish · 6 bearish · 1 mixed · 4 neutral
All BDRX filing & press-release reports (13)